v3.26.1
COLLABORATION AND LICENSE AGREEMENTS (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 12, 2026
Jan. 06, 2025
Feb. 05, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Jan. 07, 2024
Collaboration and License Agreements [Line items]                  
Gain (loss) on changes in fair value of ordinary shares       $ (244,000) $ (2,464,000) $ (3,195,000) $ (2,415,000)    
TG License | License                  
Collaboration and License Agreements [Line items]                  
Collaborative arrangement, upfront payments and liabilities   $ 2,500,000             $ 10,000,000.0
Sale of stock, number of shares issued in transaction (in shares)   220,712 97,360            
Percentage of premium over the volume-weighted-average-price of the company’s common stock (as a percent)   100.00% 100.00%            
Number of trading days prior to agreement to determine price per share   30 days 30 days            
Sale of stock, price per share (in USD per shares) $ 11.1660 $ 11.33              
Revenue recognized $ 7,500,000         6,800,000 0    
Additional milestone 288,600,000                
Contract with customer, liability, revenue recognized upon issuance of shares 700,000                
Contract with customer, liability, revenue recognized as transaction price 6,800,000                
TG License | License | Payment Tranche One                  
Collaboration and License Agreements [Line items]                  
Collaborative arrangement, upfront payments and liabilities     $ 5,250,000            
Revenue recognized 5,250,000                
TG License | License | Payment Tranche Two                  
Collaboration and License Agreements [Line items]                  
Collaborative arrangement, upfront payments and liabilities     $ 2,250,000            
Revenue recognized $ 2,250,000                
Shares available for exchange (in shares) 201,504                
Novartis Pharma AG | Discovery and Development                  
Collaboration and License Agreements [Line items]                  
Collaborative arrangement, upfront payments and liabilities       $ 0   0   $ 0  
Revenue recognized           0 100,000    
iECURE | Development and License                  
Collaboration and License Agreements [Line items]                  
Gain (loss) on changes in fair value of ordinary shares           0 $ (2,500,000)    
Agriculture Industry Collaboration Partner | Research and License                  
Collaboration and License Agreements [Line items]                  
Revenue recognized           $ 4,000,000.0